enGene Inc. Common Stock (ENGN)
| Bid | 5.45 |
| Market Cap | 298.22M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -7.44M |
| EPS (ttm) | -1.46 |
| PE Ratio (ttm) | -4.01 |
| Forward PE | -3.45 |
| Analyst | Buy |
| Ask | 6.03 |
| Volume | 17,051 |
| Avg. Volume (20D) | 143,160 |
| Open | 6.00 |
| Previous Close | 6.01 |
| Day's Range | 5.76 - 6.13 |
| 52-Week Range | 4.42 - 18.40 |
| Beta | -0.65 |
About ENGN
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calm...
Analyst Forecast
According to 9 analyst ratings, the average rating for ENGN stock is "Buy." The 12-month stock price forecast is $28, which is an increase of 378.63% from the latest price.
1 month ago · businesswire.com
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene...
2 months ago · businesswire.com
enGene Reports Full Year 2024 Financial Results and Provides a Business UpdateBOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimog...
2 months ago · seekingalpha.com
enGene Holdings: Compelling Early Data Bode Well For Their Near-Term OutlookenGene is working toward an approval similar to what IBRX got with Anktiva, although without needing BCG co-administration. NMIBC remains an area of unmet need, although it may not be SO unmet that th...
